Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2018 Nov 12;28(3):584–590. doi: 10.1158/1055-9965.EPI-18-0667

Figure 2.

Figure 2

Tristetraprolin expression in WCM prostate cancer cohorts. The top panel (A) depicts the expression of tristetraprolin for all samples in the cohort where each bar corresponds to a sample. The bottom panel (B) summarizes the data in whisker plots. Tristetraprolin expression is significantly downregulated in CRPC compared to benign prostate (Wilcoxon test p=7.1e-10) and localized prostate cancer (PCa) (p=9.0e-14).